LASEK治疗LASIK术后屈光欠矫

目的 :探讨准分子激光上皮下角膜磨镶术 (LASEK)治疗准分子激光原位角膜磨镶术 (LASIK)术后屈光欠矫的疗效。方法 :对LASIK术后屈光欠矫的 11例 (2 0只眼 )施行LASEK。结果 :术后 6个月视力和屈光度趋于稳定 ,术后 3个月角膜Haze 0级者 15只眼 ,0 5级者 4只眼 ,1级者 1只眼。术后 6个月 ,裸眼视力≥ 0 6、≥ 1 0者分别为 2 0只眼 (10 0 % )、14只眼 (70 % )。屈光度≤± 1 0 0D者为 19只眼 (95 % )。结论 :LASEK治疗LASIK术后屈光欠矫安全 ,有效。     

LASEK、PRK和LASIK治疗中低度近视的比较

目的对比分析准分子激光上皮下角膜磨镶术(LASEK)、碰光性角膜切削术(PRK)、激光原位角膜磨镶术(LASIK)治疗中低度近视临床疗效。方法LASEK组58例(112眼)随访3-9月,PRK、LASIK组各120眼随访1a以上,观察分析术后疼痛症状,裸眼视力及角膜混浊情况。结果术后1d出现疼痛症状:LASEK组:81眼(72.3％),PRK组120 眼(100.0％),LASIK组13眼(10.8％);术后3d裸眼视力≥0.8:LASEK组24眼(21.4％),PRK组27眼(22.5％),LASIK组113 眼(94.2％);术后3月存在角膜Haze:LASEK组31眼(27.6％)、PRK组94眼(78.3％),LASIK组0眼。结论LASEK后疼痛症状、角膜Haze明显减轻,疗效优于PRK;LASEK与LASIK相比没有角膜瓣相关并发症,早期视力恢复较慢。     

LASEK治疗中高度近视的临床研究

目的　观察准分子激光角膜上皮瓣下磨镶术(LASEK)治疗中高度近视的临床效果。方法　LASEK治疗4 6例 (92眼 )中高度近视 ,屈光度 - 4 .2 5～ - 17.0D ,随访 3～ 15月 ,观察症状、视力、屈光状态、角膜并发症等情况。结果　术后刺激症状与PRK类似 ,无明显haze出现。视力 :术后第 3月 ,裸眼视力≥ 0 .8者 86眼 ,≥ 1.0者 78眼 ,第 6月裸眼视力≥ 0 .8者 81眼 ,≥ 1.0者 73眼。结论　LASEK治疗中高度近视安全性更高 ,术后视觉效果更好 ,拓宽了准分子激光应用的适应证     

影响准分子激光屈光性角膜切削术疗效的多因素分析

目的:观察准分子激光屈光性角膜切削术(PRK)治疗近视、散光的疗效,探讨影响疗效的相关因素。方法:采用VISX20/2O型准分子激光仪对306例(529眼)近视、散光患者进行PRK手术。术前等值球镜屈光度为-1.00～16.00D(-6.55±3.19D),分为两组:Ⅰ组:-1.00～6.00D,294眼;Ⅱ组:-6.25～16.00D,235眼。随访3～12个月。结果:术后12个月,裸眼视力≥0.5、1.0者在Ⅰ组分别为97.5％、77.5％,在Ⅱ组分别为80.3％、32.8％;实际矫正度在预测矫正度±1.00D内者在Ⅰ、Ⅱ组分别为92.5％、42.6％。影响术后屈光度变化的因素:术后角度上皮下雾状混浊(Haze)程度、去上皮的方法、眼压、术前中央角膜厚度。结论:PRK治疗-6.00D以内的近视是一种安全、稳定、预测性强、有效的方法。术前应根据屈光度、年龄、角膜厚度、眼压、设计手术方案,术中强调采用激光去除上皮。眼科学报1997;13:75～78     

准分子激光双面式原位与上皮瓣下角膜磨镶术治疗高度近视评价

目的 比较准分子激光双面式切削原位角膜磨镶术(Both-sideLasik,BSL)和准分子激光角膜上皮瓣下磨镶术(LASEK)治疗薄角膜高度近视的临床效果,两种手术方法的优缺点.方法 应用BSL和LASEK治疗近视度>-8.00D,角膜厚度471～546μm的患者.BSL组45例51只眼,近视球镜度数为-8.25～-13.25D,平均-9.71D.LASEK组39例67只眼,近视球镜度数-8.25～-12.75D,平均-926D.分别于术后10d、1、3、6、12个月检查裸眼视力,矫正视力,屈光度和角膜雾样混浊(Haze)等,并进行比较.结果 BSL组术后反应轻,裸眼视力恢复快,术后10d、1、3、6、12个月裸眼视力达到术前最佳矫正视力的比例,BSL组分别为为72.55%、80.39%、84.31%1.31%、78.43%和68.63%,LASEK组分别为47.76%、65.67%、71.64%、70.15%和61.19%,未出现矫正视力下降2行及以上者.两组屈光度均由手术早期的过矫逐渐转变为后期的欠矫,LASEK组发生Haze的比例明显高于BSL组,差异有统计学意义(P<0.05),但多为0.5～1级Haze,术中、术后无严重并发症.结论 准分子激光双面式切削原位角膜磨镶术治疗薄角膜高度近视安全、有效,与LASEK相比,其角膜雾样混浊发生率更低,且程度轻,视力恢复更快.     

准分子激光屈光性角膜切削术治疗近视、散光术后3年疗效分析

目的 为了评价准分子激光屈光性角膜切削术治疗近视、近视散光的远期疗效。方法 应用美国VISX 20/20型准分子激光仪,治疗132例(259眼),采用多切削区治疗屈光度-1.5D～-16.0D的近视观察3年以上,按术前球镜屈光度分为二组:Ⅰ组-1.5D～-6.0D(196眼),Ⅱ组-6.25D～-16.0D(73眼)。结果 术后3年裸眼视力≥0.5,在Ⅰ、Ⅱ中组中分别为94.6％、89.3％;术后3年裸眼视力≥1.0,在Ⅰ、Ⅱ组中分别为90.7％、70.5％,角膜HazeⅠ组0级90.3％,0.5级9.7％,无1级以上Haze;Ⅱ组0级63.0％,0.5级34.2％,1级2.8％,无2级以上Haze。结论 准分子激光屈光性角膜切削术对低、中、高度近视、近视散光均取得良好的远期效果,但对低、中度近视效果更佳,对高度近视预测性较差。     

准分子激光角膜切削术(PRK)治疗低、中度近视远期临床分析

目的 :评价准分子激光角膜切削术 (PRK)治疗低、中度近视的远期疗效。方法 :对 12 80眼屈光度为 -2 0～ -6 0DPRK术后六年以上患者进行视力、屈光度、并发症随访观察。结果 :PRK术后六年裸眼视力 >1 0者 1178眼 ( 92 % ) ,1 0～ 0 8者 5 3眼 ( 4 1% ) ,<0 8～ 0 6者 49眼 ( 3 9% ) ,仅 6眼视力下降一行。屈光度± 0 5D 112 8眼 ( 88 1% ) ,-0 5～ -1 0D15 2眼 ( 11 9% )。结论 :准分子激光角膜切削术治疗低、中度近视的远期疗效可靠。     

中低度近视的准分子激光上皮瓣下角膜磨镶术

目的探讨准分子激光上皮瓣下角膜磨镶术(LASEK)治疗中低度近视的疗效与安全性。方法应用德国ZeissMEL80准分子激光器对<-6.00D的中低度近视患者102例200眼施行LASEK术,术前平均裸眼视力0.17±0.13(0.02～0.6),平均等值球镜-3.87±1.57D。前瞻性地随访6个月,观察术后症状、裸眼和最佳矫正视力、显然屈光度、眼压、角膜愈合程度和并发症。结果LASEK术后6个月裸眼视力≥0.6者占100%,裸眼视力≥1.0者占96%。术后平均裸眼视力1.08±0.23,平均等值球镜-0.35±0.41D。平均角膜上皮愈合时间1～5天。术后10眼(5%)出现haze,0.5级8眼,1.0级2眼。1例患者出现眩光。结论LASEK是一种安全、有效的治疗中低度近视的屈光手术。     

准分子激光屈光性角膜切削术治疗近视的临床分析

目的：评价准分子激光屈光性角膜切削术（PRK）治疗不同程度近视的疗效。方法：应用SchwindKeratomF准分子激光机对1995眼不同程度近视（－0．75～15．50D）行PRK治疗。按屈光度分三组：组Ⅰ≤－6．00D,873眼;组Ⅱ－6.25D—－10．00D,774眼;组Ⅲ＞－10．00D,348眼。术后12个月,对三组术后的视力、屈光度及Haze进行随访比较。结果：术后12个月Ⅰ、Ⅱ、Ⅲ组裸眼视力≥0．5者分别为986%,94．2％和60.04％;≥1.0者分别为85．5％,71.3％和25.9％;屈光度在±1．00D以内分别为90．5％,68．8％和29．3％。角膜雾状混浊（Haze）≥2级者分别为0.8％,11．5％和13．7％。结论：PRK治疗中低度近视疗效较好,对高度和超高度近视由于术后Haze和屈光度回退发生率增高,疗效受到明显影响,有待进一步完善手术方法和术后用药等问题。     

LASIK治疗近视散光的临床观察

目的:观察准分子激光原位角膜磨镶术(laser in situ kera-tomileusis,LASIK)治疗近视散光的临床疗效。方法:应用鹰视准分子激光治疗系统对120例234眼近视散光进行LASIK手术治疗。随访12mo,比较手术前后的视力、屈光度、散光及其散光轴位的变化。结果:术后随访12mo,裸眼视力≥术前最佳矫正视力(BCVA)者108例213眼(91%),屈光度在±1.00D以内者112例222眼(94.8%),散光残留平均为-0.52D。结论:LASIK治疗近视散光效果好,稳定性高,安全可靠。     

Laser subepithelial keratomileusis for myopia of -6 to -10 diopters with astigmatism with the MEL60 laser

PURPOSE: To evaluate the efficacy, predictability, and safety of laser subepithelial keratomileusis (LASEK) for treatment of high myopia with astigmatism. METHODS: LASEK was performed in 61 eyes of 36 consecutive patients with myopic spherical equivalent refraction of -6.00 to -10.00 D using the Aesculap-Meditec MEL60 excimer laser. Data were collected prospectively with a follow-up of 6 to 17 months. Main outcome measures recorded were UCVA, BSCVA, residual refractive error, corneal haze, and complications. RESULTS: Ninety-six percent of eyes achieved 20/40 or better UCVA at 1 month. At 12 months, 64% of eyes achieved 20/20 and 92% achieved 20/40 or better UCVA. Two eyes lost 2 lines of BSCVA at 6 or 12 months. Accuracy of correction was +/- 0.50 D from emmetropia in 82% of eyes, and +/- 1.00 D in 90% at 12 months. No eye showed more than grade 1 haze. Grade 1 haze was observed in three eyes at 12 months. One patient had mild postoperative keratitis, which was successfully treated. CONCLUSIONS: LASEK with the Aesculap-Meditec MEL60 excimer laser appeared to be safe, effective, and highly predictable in treating high myopia.     

Laser in situ keratomileusis versus laser-assisted subepithelial keratectomy for the correction of high myopia

PURPOSE: To compare the visual and refractive outcomes of laser in situ keratomileusis (LASIK) and laser-assisted subepithelial keratectomy (LASEK) in the treatment of high myopia. SETTING: Institute of Vision Research, Department of Ophthalmology, College of Medicine, Yonsei University, and Balgeunsesang Ophthalmology Clinic, Seoul, South Korea. METHODS: Four hundred seventy eyes of 240 patients with manifest refraction spherical components greater than -6.00 diopters (D) were assigned to 2 groups: 324 eyes (167 patients) were treated with LASIK and 146 eyes (73 patients), with LASEK. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), remaining refractive error, corneal haze, and complications were followed in both groups for 12 months. RESULTS: At 12 months, the mean spherical equivalent (SE) was within +/-0.50 D of emmetropia in 205 eyes (63.3%) in the LASIK group and 81 eyes (55.5%) in the LASEK group and within +/-1.00 D in 261 eyes (80.6%) and 104 eyes (71.2%), respectively. The UCVA was 20/25 or better in 269 LASIK eyes (83.0%) and 111 LASEK eyes (76.0%). There was more than a 1-line loss of BSCVA in 4 LASIK eyes (1.2%) and 21 LASEK eyes (14.3%). The between-group differences in SE, magnitude of cylinder, UCVA, and haze were statistically significant (P<.05). CONCLUSIONS: Both LASIK and LASEK were safe and effectively treated eyes with high myopia. Laser in situ keratomileusis provided superior results in visual predictability and corneal opacity.     

LASEK治疗中高度近视疗效分析

目的:观察准分子激光上皮瓣下角膜磨镶术(LASEK)治疗中高度近视的临床效果。方法:对46例85眼中度以上近视进行LASEK矫正,根据等效球镜度分为I组(-3.25～-6.00)D、II组(-6.25～-10.00)D、III组(-10.25～-12.9)D。观察术后裸眼视力和最佳矫正视力、显然屈光度、眼压及haze情况。术后随访6mo以上。结果:术后6mo时裸眼视力达到术前最佳矫正视力或更好者3组分别为100%,78%,75%,裸眼视力≥0.5分别为100%,96%,88%,未见最佳矫正视力较术前最佳矫正视力低于2行以上的眼;3组的屈光度稳定在±1.00D内者分别为68.4%,58.0%,43.7%;3组的平均屈光度分别为(-0.38±0.66)D、(-0.77±1.25)D、(-1.25±1.97)D。II组和III组术后发生不同程度的haze(≤2级)。结论:LASEK治疗中高度近视安全有效。haze和屈光回退是治疗高度和超高度近视主要并发症,从某种角度说,控制了haze的发生也就在很大程度上控制了术后的屈光回退的速率。     

激光角膜上皮瓣下磨镶术和激光原位角膜磨镶术治疗中高度近视的对比研究

目的比较激光角膜瓣下磨镶术(LASEK)和激光原位角膜磨镶术(LASIK)治疗中高度近视的临床效果. 方法中高度近视患者198例(394只眼).其中LASEK手术治疗93例(184只眼), LASIK手术治疗105例(210只眼). 结果术后1天,LASIK 组28 %裸眼视力达到1.0,LASEK组无1例裸眼视力达到1.0.术后1周、1、3、6月裸眼视力大于或等于1.0者,两组比较差异无显著性 (P=0.36,P=0.58,P=0.44,P=0.64).角膜地形图分析平均角膜中央屈光力与周边屈光力的差异,LASEK组(0.69)明显小于LASIK组(2.62).结论 LASEK手术矫正中高度近视均有良好的治疗效果,是一种安全、有效、预测性好的屈光手术.     

Epi-LASIK治疗中高度近视术后视觉质量的临床研究

目的:研究机械法准分子激光角膜上皮瓣下磨镶术(Epi-LAS1K)矫治中、高度近视对视觉质量的影响。方法:回顾分析采用Epi-LAS1K手术矫治中、高度近视并随访1a的病例128例256眼的临床资料。患者根据术前等效球镜分为3组:A组:<-3.00D,均值-2.11±0.35D(30例60眼);B组:-3.00D～-6.00D,均值-4.93±0.68D(46例92眼);C组:>-6.00D,均值-8.45±1.62D(52例104眼)。手术采用美国AMO公司AmadeusⅡ自动角膜板层刀制作上皮瓣,以德国ZEISS公司MEL80型准分子激光仪进行激光切削,术后配戴绷带式角膜接触镜7d,术后随访时间为1,7d;1,3,6mo;1a,研究术后视力和屈光状态、高阶像差及haze形成情况。结果:术后随访1a,A组58眼(97%)的UCVA>1.0,B组87眼(95%)的UCVA>1.0,C组89眼(86%)的UCVA>1.0;A组60眼(100%)等效球镜屈光度数在预期值的±1.00D内,B组92眼(100%)等效球镜屈光度数在预期值的±1.00D内,C组7眼(7%)等效球镜屈光度数大于预期值的±1.00D。术后高阶像差较术前增大(P<0.05),B组与C组各时间点与A组相比无统计学意义。A组术后1mo有3眼(5%)的患者有0.5级haze,术后3mo有1眼(2%)的患者有0.5级haze,术后6mo到1a,所有患者均无明显haze;B组术后1mo有6眼(7%)的患者有0.5级haze,术后3mo有4眼(4%)的患者有0.5级haze,术后6mo～1a,所有患者均无明显haze;C组术后1mo有10眼(10%)的患者有0.5级haze,2眼(2%)的患者有Ⅰ级haze,术后3mo有8眼(8%)的患者有0.5级haze,2眼(2%)的患者有Ⅰ级haze,术后6mo有5眼(5%)的患者有0.5级haze,术后1a所有患者均无明显haze。结论:Epi-LAS1K手术术后具有视力恢复满意,haze程度轻等优点,是治疗中、高度近视的一种安全、有效的手术方式。     

Laser-assisted subepithelial keratectomy for low to high myopia and astigmatism

PURPOSE: To evaluate the safety and efficacy of laser-assisted subepithelial keratectomy (LASEK) for the treatment of low to high myopia and astigmatism. SETTING: Solo private practice, Mountain View, California, USA. METHODS: Laser-assisted subepithelial keratectomy was performed in 146 eyes of 83 consecutive patients with myopia or myopic astigmatism using a VISX Star S2 excimer laser (72 eyes) or a Nidek EC-5000 excimer laser (74 eyes). The mean preoperative myopic spherical equivalent was -5.32 diopters (D) (range -1.25 to -14.38 D). Data were collected prospectively with a follow-up of 1 to 12 months. Outcome measurements included uncorrected visual acuity (UCVA), manifest refraction, best spectacle-corrected visual acuity (BSCVA), corneal haze, and complications. RESULTS: After 6 and 12 months, no eye lost 2 or more lines of BSCVA. After 6 months, the UCVA was 20/20 in 57% of eyes and 20/40 or better in 96%. After 12 months, it was 20/20 in 56% of eyes and 20/40 or better in 96%. No eye developed corneal haze that affected visual acuity. There were no serious or vision-threatening complications. CONCLUSIONS: Laser-assisted subepithelial keratectomy was safe and effective in treating a wide range of myopia and astigmatism. The potential advantages of LASEK over laser in situ keratomileusis (LASIK) include the elimination of stromal flap complications and greater choice in patient selection. The disadvantages include varying degrees of pain for 2 days and blurry vision for several days postoperatively.     

Comparison between LASEK with mitomycin C and LASIK for the correction of myopia of -7.00 to -13.75 D

PURPOSE: To compare laser epithelial keratomileusis (LASEK) and LASIK for the correction of high myopia. METHODS: A prospective, single-masked study was conducted. Patients treated with LASEK to correct myopia > or = -7.00 diopters (D) (spherical equivalent manifest refraction) with a cylinder < or = -3.50 D (LASEK group) were compared to patients treated with LASIK (LASIK group) using the same excimer laser (Technolas 217C). Mitomycin C (MMC) 0.02% was applied for 1 minute in all LASEK-treated eyes. RESULTS: A total of 228 consecutive eyes were included in the study (114 in each group, matched for preoperative refraction). The mean preoperative spherical equivalent manifest refraction was -8.72 +/- 1.20 D in the LASEK group and -8.74 +/- 1.20 D in the LASIK group (range: -7.00 to -13.75 D) (P = .9). Uncorrected visual acuity (UCVA) was significantly lower in LASEK eyes 1, 7, and 30 days postoperatively (P = .0001 for each comparison). No significant differences were found at 3 months postoperatively in UCVA (P = .3), best spectacle-corrected visual acuity (BSCVA) (P = .2), or in the safety (P = .6) and efficacy (P = .8) indices. Uncorrected visual acuity was 1.0 or better in 34.2% of LASEK eyes and 44.7% of LASIK eyes. Spherical refraction was +0.25 +/- 0.6 D after LASEK and -0.06 +/- 0.5 D after LASIK (P = .0001). Sixty-eight percent of LASEK eyes and 79% of LASIK eyes were within +/- 0.50 D of intended refraction. No LASEK eye versus 7 LASIK eyes lost 2 lines of BSCVA. Eight LASEK eyes gained 2 or more lines of BSCVA versus 1 LASIK eye. CONCLUSIONS: Visual improvement after LASEK with intraoperative MMC was significantly slower than after LASIK. Visual outcomes (UCVA, BSCVA, and safety and efficacy indices) 3 months after surgery were similar with both techniques for the correction of high myopia. Ten percent more eyes after LASIK were within +/- 0.50 D of intended refraction.     

Prospective, randomized, paired comparison of laser epithelial keratomileusis and photorefractive keratectomy for myopia less than -6.50 diopters

PURPOSE: We compared predictability, efficacy, safety, and patient satisfaction following laser epithelial keratomileusis (LASEK) and photorefractive keratectomy (PRK) for low to moderate myopia with either the Nidek EC-5000 excimer laser or the Technolas 217C excimer laser. METHODS: Forty-two patients with spherical equivalent refraction in the range -1.00 to -6.50 D were enrolled in this prospective study, each randomized for choice and sequence of LASEK and PRK on each of their eyes. Patients were examined daily for 7 days, and at 1 and 3 months. Patient satisfaction and quality of vision were assessed using a subjective questionnaire. RESULTS: Mean baseline refraction was -3.57 +/- 1.25 D in LASEK eyes and -3.44 +/- 1.13 D in PRK eyes. Follow-up rates were 100% up to 1 month and 76% at 3 months. At 3 months, 32 (100%) of LASEK eyes and 31 (97%) of PRK eyes had uncorrected visual acuity > or = 20/40, 25 (79%) of LASEK eyes and 26 (82%) of PRK eyes had uncorrected visual acuity > or = 20/20, mean refraction was 0.08 +/- 0.53 D in LASEK eyes and 0.12 +/- 0.50 D in PRK eyes, 26 (81%) of LASEK eyes and 23 (72%) of PRK eyes had a refraction within +/- 0.50 D and 29 (91%) of LASEK eyes and 30 (94%) of PRK eyes had refraction within +/- 1.00 D. Epithelial healing time and pain in LASEK and PRK eyes were not statistically different, and patients were equally satisfied. CONCLUSION: LASEK had similar predictability, efficacy, safety, and patient satisfaction to PRK in the treatment of low to moderate myopia.     

Laser-assisted subepithelial keratectomy and photorefractive keratectomy for the correction of hyperopia. Results of a 2-year follow-up

PURPOSE: To evaluate and compare the efficacy, safety, predictability, and stability of laser-assisted subepithelial keratectomy (LASEK) and photorefractive keratectomy (PRK) for low to moderate hyperopia with a 2-year follow-up. SETTING: Department of Ophthalmology, Masaryk University Hospital, Brno, Czech Republic. METHODS: This prospective comparative single-surgeon study included 216 eyes of 108 patients with hyperopia who received PRK in 1 eye and LASEK in the contralateral eye. The mean patient age was 38.3 years (range 25 to 58 years). The mean preoperative spherical equivalent (SE) cycloplegic refraction was +3.67 diopters (D) +/- 1.15 (SD) (range +2.00 to +5.00 D), and astigmatism was less than 1.00 D. In each patient, PRK was performed in 1 eye (Group A) and LASEK was performed in the other eye (Group B) using the Nidek EC-5000 excimer laser. Postoperative uncorrected visual acuity (UCVA), best corrected visual acuity, contrast sensitivity, manifest and cycloplegic refractions, refractive stability and predictability, postoperative pain, and corneal haze were examined and statistically analyzed. A P value less than 0.05 was considered significant. RESULTS: At 1 week, the UCVA was 20/40 or better in 58% of PRK eyes and 85% of LASEK eyes (P =.037); at 2 years, it was 20/40 or better in 81% and 91%, respectively (P =.076). At 2 years, the UCVA for near was N8 or better in 73% of PRK eyes and 89% of LASEK eyes (P =.064). No patient lost 2 or more lines of Snellen visual acuity. The safety index was 1.03 in PRK eyes and 1.08 in LASEK eyes. Refractive stability was achieved at 6 months in LASEK eyes and at 12 months in PRK eyes. The mean SE cycloplegic refraction decreased from +3.58 D (PRK eyes) and +3.76 D (LASEK eyes) at baseline to +0.74 D and +0.32 D, respectively, at 2 years; in 57% and 78% of eyes, respectively, the refraction was within +/-0.50 D of the targeted refraction. Peripheral corneal haze scores at 3 to 9 months and pain scores at 1 to 3 days were significantly lower in the LASEK group than in the PRK group. CONCLUSIONS: Laser-assisted subepithelial keratectomy for hyperopia up to +5.00 D provided good visual and refractive results. It significantly reduced postoperative pain, grade of peripheral ring-shaped corneal haze, and regression of hyperopia. Hyperopic LASEK provided quicker visual recovery and achieved better efficacy, predictability, and refractive stability than hyperopic PRK.     

LASEK治疗高度及超高度近视的临床观察

目的:评价LASEK治疗高度、超高度近视的临床效果。方法:回顾2008-07/2010-01在我院行LASEK手术的271例493眼患者,按术前等值屈光度分为高度近视组(6.00～10.00D)与超高度近视组(≥10.00D),其中高度组311眼,超高度组182眼。随访1a,比较术后两组的裸眼视力、haze及其它并发症。结果:术后裸眼视力均较术前提高。随访结束,裸眼视力≥术前最佳矫正视力(BCVA)眼数为,高度组255眼(82.0%),超高度组110眼(60.4%),两者统计有显著性差异(P<0.01)。术后haze均在2级之内;无明显的角膜刺激症状及严重并发症出现。结论:LASEK治疗高度近视安全、有效,但对超高度近视的治疗效果不佳。